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Abstract 
Background: Preclinical trials have shown beneficial effects of nerve growth factor (NGF) administration on visual 
function in animal models of retinitis pigmentosa (RP). The aim of this pilot study was to explore the potential efficacy 
of short term NGF eye drops treatment in patients affected by RP.
Methods: The trial consisted in 10 days daily administration of murine NGF as eye‑drops for a total dose of 1 mg 
NGF/pt. Eight RP patients at an advanced stage of the disease were included in the trial. To monitor safety and 
potential adverse effects subjects underwent standard clinical measures and were requested to report any general or 
topic alterations following NGF assumption. Retinal function was assessed at baseline and after treatment by best‑
corrected visual acuity measurement (BCVA), macular focal electroretinogram (fERG) recording and Goldmann visual 
field testing.
Results: A transient tolerable local corneal irritation was the only adverse effect reported. fERG and BCVA remained 
within the limits determined by test–retest analysis of a large cohort of RP patients. Three patients reported a subjec‑
tive feeling of improved visual performance. This was associated to a temporary enlargement of the visual field in all 
three patients and to improved fERG in two of the three.
Conclusions: Short‑term administration of NGF eye‑drops caused neither significant adverse effects nor visual 
function losses in the tested RP patients. A minority of patients experienced an improvement of visual performance 
as shown by Goldmann visual field and fERG. This study supports the safety and possible efficacy of NGF eye‑drops 
administration in RP patients.
Trial registration: EudraCT n. 2008‑004561‑26
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Background
Inherited retinal dystrophies of photoreceptors such 
as retinitis pigmentosa (RP) are an important cause of 
severe vision loss.
There is presently no cure for RP, but considerable 
effort is devoted to the search of rescue strategies. Even 
if the exact mechanisms leading to photoreceptor death 
in the various phenotypes of retinal degeneration are 
not fully understood, photoreceptor apoptosis is consid-
ered to be the final common event in the disease process 
[1–3]. Because of their ability to inhibit the apoptotic 
cascade, neurotrophic factors may represent a promising 
therapeutic strategy in RP. This was first demonstrated by 
slowing down progressive photoreceptors loss in Royal 
College of Surgeons (RCS) rats following intravitreal 
injection of basic fibroblast growth factor (bFGF) [4].
The neurotrophins (NTs) are a family of peptide growth 
factors homologous to Nerve Growth Factor (NGF) that 
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function of neuronal cells. There is evidence that exog-
enous NT administration promotes photoreceptor sur-
vival in animal models of both light induced [5–9] and 
inherited retinal degeneration [8, 10–12].
Among NTs, NGF seems particularly promising for 
testing. Its exogenous administration has been shown to 
promote photoreceptor survival in animal models of RP 
[10, 11].
Furthermore, preclinical evidence in rodents shows sig-
nificant availability of this NT in the retina following its 
administration as eyedrops [13]. Indeed, clinical studies 
also suggest NGF eyedrops biological activity in the vis-
ual system of patients with glaucomatous optic neuropa-
thy [14] and childhood optic glioma [15, 16].
One possible limitation of the use of neurotrophic fac-
tors is their potential negative effect on photoreceptor 
function, as a result of downregulation of phototransduc-
tion cascade enzymes. It is indeed known, from both pre-
clinical [17] and clinical [18] studies, that the NTs bFGF 
and ciliary neurotrophic factor (CNTF) may depress 
retinal sensitivity as shown by electroretinogram [17] and 
visual field examination [18]. Thus a functional negative 
effect may represent the price to be paid to obtain photo-
receptor neuroprotection.
The aim of this investigation was to investigate the 
potential efficacy and adverse effects of murine NGF eye-
drops administration in RP patients.
Methods
The present pilot study (EudraCT n. 2008-004561-26) 
followed the tenets of the Declaration of Helsinki and 
was approved by the ethics committee of the institution. 
All the enrolled patients were fully informed as to the 
nature and goals of the study. Written informed consent 
was obtained from all patients.
Patient recruitment and Inclusion criteria
Sixteen eyes of 8 patients (6 males, 2 females; average 
age 49.7  ±  14.3  years) affected by RP were included 
in the study (Table  1). All patients had progressive 
forms of RP based on history, clinical findings and 
ERG abnormalities. Furthermore, patients met the 
following inclusion criteria: (1) typical RP with a rod-
cone pattern of retinal dysfunction, as determined by 
standard Ganzfeld electroretinography, dark-adapted 
Tuebinger perimetry, and classic fundus appearance. 
(2) Advances stage of the disease (at baseline: central 
portion of visual field with Goldman V/4e  <15  deg; 
fERG  <1 uV). (3) Known inheritance pattern and/or 
genotype under study. (4) At least 1 years of fERG and 
clinical examination follow-up, with a minimum of 
three visits. (5) No or minimal ocular media opacities. 
(6) No concomitant ocular (e.g. glaucoma, amblyopia) 
or systemic diseases. Patients with non- Usher syndro-
mic sub-types of RP, Leber’s congenital amaurosis or 
early onset RP with atypical functional patterns were 
excluded.
Measures of ocular function and electroretinography
A full general and ophthalmologic examination (includ-
ing detailed family history, anterior segment biomi-
croscopy, BCVA, direct and indirect ophthalmoscopy, 
intraocular pressure measurement) was performed on 
each patient at baseline.
Best-corrected visual acuities were obtained with a 
projected Snellen chart. Kinetic visual fields were meas-
ured to the V4e white test light of the Goldmann perim-
eter against the standard background of 31.5 apostilbs. 
Goldmann visual fields were digitized and total visual 
field areas were calculated.
Cone focal ERGs (fERG) were recorded from the cen-
tral 18° region using a uniform red field superimposed 
on an equiluminant steady adapting background, used 
to minimize stray-light modulation [19, 20]. The stimu-
lus was generated by a circular array of eight red LEDs 
(λ maximum, 660 nm; mean luminance, 93 cd/m2) pre-
sented on the rear of a Ganzfeld bowl (white-adapting 
background). A diffusing filter in front of the LED array 
Table 1 Patient details
a Averaged between eyes
Patient# Gender Age Inheritance Genetic mutation BCVAa (decimal) fERGa (mV)
1 M 38 Autosomal recessive CERKL R257X (homozygous) 0.39 0.30
2 M 28 Autosomal recessive Unknown 0.17 0.09
3 M 59 Autosomal dominant Unknown 0.85 0.58
4 M 69 Autosomal recessive CRX V242M (heterozygous) 0.32 0.12
5 F 48 Autosomal dominant RHO R135W 0.10 0.41
6 F 62 Autosomal recessive Unknown 0.05 0.30
7 M 57 Autosomal dominant Unknown 0.57 0.16
8 M 37 X‑linked Unknown 0.10 0.27
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made it appear as a circle of uniform red light. fERGs 
were recorded in response to the sinusoidal 95 % lumi-
nance modulation of the central red field. Flickering 
frequency was 41  Hz. Patients fixated monocularly at 
a 0.25° central fixation mark, under the constant moni-
toring of an external observer. Pupils were pharma-
cologically (1  % tropicamide and 2.5  % phenylephrine 
hydrochloride) dilated to a diameter  ≥8  mm, and all 
subjects underwent a pre-adaptation period of 20 min to 
the stimulus mean luminance. fERGs were recorded by 
an Ag–AgCl electrode taped on the skin over the lower 
eyelid. A similar electrode, placed over the eyelid of the 
contralateral patched eye, was used as reference (inter-
ocular recording). fERG signals were amplified (106-
fold), bandpass filtered between 1 and 100 Hz (6 dB/oct), 
and averaged (12-bit resolution, 2-kHz sampling rate, 
200–600 repetitions in 2–6 blocks). Off-line discrete 
Fourier analysis quantified the amplitude and phase lag 
of the response fundamental harmonic (1st harmonic) at 
41 Hz.
Ocular and systemic complications potentially related 
to ngf administration
During the entire period of assessment (40  days; see 
below) particular attention was paid to detect ocular and/
or systemic side effects. Potential ocular complications 
included inflammation (external or uveitis), pain, devel-
opment of lens opacities, and increased intraocular pres-
sure. Systemic complications previously reported in the 
literature include allergic reactions, systemic pain as well 
as weight loss [21].
A comprehensive medical evaluation was carried out 
by a general physician at day zero, and at the end of the 
NGF treatment. All patients received oral and written 
information about the experiment procedures before 
signing the informed consent.
Nerve growth factor isolation
NGF (2.5S) was purified from male mouse submandibu-
lar glands as already described [15, 22]. Briefly, the extract 
of submandibular glands of adult male mice was passed 
through subsequent cellulose columns, to separate NGF 
by adsorption. NGF-containing fractions were analyzed 
by spectrophotometry and Western blot analysis. NGF 
purity (>95 %) was estimated by high-performance liquid 
chromatography, while its biological activity was evalu-
ated by neurite outgrowth stimulation in rat PC12 cells. 
Purified NGF was dialyzed, lyophilized under sterile con-
ditions, and stored at −20  °C until used. At the time of 
use, purified NGF was dissolved in 0.9  % sterile saline 
solution in concentrations of 200 µg/mL. The concentra-
tion of NGF in this solution was stable over the 10  day 
treatment time.
NGF administration schedule
A total of 1  mg of NGF diluted in 5  mL of saline solu-
tion was administered in the form of eye drops onto the 
conjunctiva of both eyes for 10 consecutive days 3 times 
a day. This amount is considered sufficient to reach and 
stimulate NGF receptors in most cerebral choliner-
gic areas of the brain and optic pathways, as previously 
reported [13]. We preferred to use murine NGF, instead 
of human-recombinant NGF, because contrasting results 
have been reported on the efficacy of the latter, mainly 
due to a lack of in vivo studies [16].
Testing schedule
fERG examinations were performed at baseline, at the 
end of the 10  days period of NGF administration and 
30 days later. BCVA measurement and Goldmann visual 
field examination were performed at baseline and 30 days 
after the end of NGF administration.
Data analysis
Changes in BCVA and fERG amplitude obtained after 
treatment were evaluated as individual changes, as well 
as in the contest of test–retest variability data obtained 
from a large cohort of RP patients followed clinically at 
the Visual Electrophysiology Service of the Institute of 
Ophthalmology at Universita’ Cattolica del S. Cuore, 
which have been subject of a long term follow-up study 
[23].
In each patient, the pre and post treatment total areas 
of Goldmann visual fields were compared. A percent-
age difference >20 % was considered clinically significant 
according to previous studies on test–retest variability in 
patients with RP [24].
Results
Both clinical and subjective reports showed that none of 
the patients suffered any adverse reaction, except for mild 
and transient conjunctival hyperemia and ocular pain, as 
already reported in previous studies administering NGF 
eye drops [25].
Individual macular focal ERG (fERG) time courses over 
the trial are shown in Fig.  1. Figure  1a summarizes the 
results, showing individual patient data averaged between 
the two eyes at baseline and at the end of the trial. Indi-
vidual eye data before, at end of the 10 days NGF treat-
ment and 30 days afterwards are shown for each patient 
in Fig. 1b. The same symbol-patient association is used in 
all Figures to allow identification of each case.
fERG changes over this period of time are heterogene-
ous among patients, with both improvements and dec-
rements. To place these measures in context, we plotted 
the overall fERG changes in each patient eye from base-
line to end of trial against the background of test–retest 
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variability in fERG measures observed in a large database 
of RP patients followed by our Ophthalmology Clinic 
(Fig. 2). This comparison showed that all but 2 cases were 
within the 10–90 percentiles limits of test–retest vari-
ability for fERG measures in RP patients. Indeed, when 
considered as a population, fERG changes over the trial 
period that did not statistically differ from the fERG 
changes observed in the test–retest variability data in the 
above mentioned RP patient database (2-sample Student 
t test P =  0.48  N =  8 present trial; N =  47 test–retest 
fERG data from RP database). Interestingly, however, the 
two trial cases showing a larger improvement than vari-
ability cut-offs also reported subjective improvement of 
visual performance (see below).
Individual best corrected visual acuity (BCVA) meas-
ures at baseline and 30 days after the end of NGF treat-
ment are shown in Fig.  3a, b for either eye of the eight 
trial patients.
BCVA changes over this period of time were hetero-
geneous among patients, but remained within the lim-
its of BCVA test–retest variability in the database of 
RP patients followed for over 4  years by our Ophthal-
mology Clinic (Fig.  4). When measuring BCVA rela-
tive changes as the ratio between Delta(logMAR) and 
average(logMAR) before and at the end of treatment, 
the difference between BCVA variation over trial and 
test–retest variability in RP patients was not statisti-
cally significant (Student t-test, P = 0,7157, N = 16 eyes 
from 8 NGF treated eyes; 35 eyes from 18 RP database 
patients).
After treatment, the area of Goldmann V4e isopter 
significantly (>20 %) increased in 3 patients (37.5 %), as 
shown in Fig. 5, and was unchanged in the remaining 5 
patients (62.5 %). None of the patients had worsening of 
kinetic visual field. Interestingly, all patients with visual 
Fig. 1 Macular focal ERG (fERG) time course in NGF treated RP patients. Individual patient fERGs averaged between the two eyes are shown in 
(a), single eye data are shown in (b). For the sake of simplicity data collected soon after the end of treatment (10 days) are only shown in (b). Each 
patient is identified by the same symbol in (a, b). Patient‑symbol association is indicated below the graphs
Fig. 2 Macular focal ERG (fERG) changes following NGF treatment 
in the context of RP patient test–retest fERG variability. Black symbols 
correspond to the NGF treated patient (same patient‑symbol 
association as in Fig. 1), gray circles are test–retest data from long 
term follow‑up RP patients from the clinic database (N = 94 eyes 
from 47 patients). Dotted horizontal lines represent the 10 and 90th 
percentile of the test–retest data sample. Average test–retest time 
span 130 ± 76 days. Each patient is identified by the same symbol as 
in Fig. 1
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field enlargement reported subjective improvement of 
visual performance and two of three patients showed an 
increase of fERG amplitude beyond test–retest variability 
90th percentile.
Discussion
The present pilot study was designed to explore the 
potential neuroprotective effect of NGF eye-drops in 
patients affected by RP.
No significant general adverse effects were clinically 
recorded nor reported by any patient. Only minor ocu-
lar side effects such as conjunctival hyperemia and ocular 
pain were reported, in line with previous studies using 
NGF eye-drops in other ocular pathologies [25].
Furthermore, no adverse changes in central retinal 
function were found in either BCVA or macular cone 
flicker ERG recorded with a specialized sub-microvolt 
technique developed in our laboratory, nor reported 
subjectively by the subjects. This is particularly relevant 
considering that previous studies based on the same 
rationale of testing neurotrophins for neuroprotection, 
found reduced central retinal sensitivity in most study 
eyes receiving implants of the neurotrophin CNTF 
[18].
Interestingly, three patients experienced a subjective 
improvement of visual performance confirmed by a sig-
nificant enlargement of Goldmann visual field and, in 
two cases, by an increase of macular cone function as 
determined by fERG. This data apparently indicates that 
NGF eye drops administration may improve retinal func-
tion at least in some cases with RP suggesting that NGF 
may exert a neuroprotective and/or neuro-enhancement 
effect in these patients. The neuroprotective effect of 
NGF on photoreceptor cells has been already demon-
strated in animal models of RP. In 1996, Lambiase and 
Aloe showed that intravitreal and retrobulbar injection 
of NGF caused a significant delay of retinal degenera-
tion with preservation of the outer nuclear layer (ONL) 
in C3H mice10.
Additionally, Lenzi et al [11] reported that retrobulbar 
injection of NGF reduced ONL thinning in RCS rats.
The exact mechanism responsible for the neuro-
protective effect of NGF on photoreceptors is still 
unknown. There is a large body of evidence demon-
strating that, in the mammalian retina [26–29], NGF 
receptors are expressed in Müller and retinal gan-
glion cells (RGC) but not in the ONL suggesting that 
the neuroprotective effect of NGF on photoreceptor 
cells may be probably indirect. As already suggested 
by Whalin et al. [30, 31], neurotrophins may bind their 
receptors on Müller cells and increase the release of 
multiple growth factors that may act on photorecep-
tor cells. This hypothesis seems to be confirmed by 
the finding that, in RCS rats [11], retrobulbar admin-
istration of NGF enhanced the expression of multiple 
growth factors including brain-derived neurotrophic 
factor (BDNF), FGF, transforming growth factor beta 
(TGF-β), vascular endothelial growth factor (VEGF) 
and neuropeptide-Y (NPY). Furthermore, it has been 
demonstrated that NGF may increase outer retina oxy-
genation by modulating the expression of VEGF in the 
RGC layer [32]. As suggested by Abed et  al [33], the 
Fig. 3 Best corrected visual acuity (BCVA) time course in NGF treated 
RP patients. Individual patient BCVA in either eye are shown before 
and 30 days after the end of NGF treatment. Each patient is identified 
by the same symbol as in Fig. 1
Fig. 4 Best corrected visual acuity (BCVA) changes following NGF 
treatment in the context of RP patient test–retest BCVA variability. 
Black symbols correspond to the NGF treated patient (same patient‑
symbol association as in Fig. 1), gray circles are test–retest data 
available from long term follow‑up RP patients in the clinic database 
(N = 35 eyes from 18 patients). Dotted horizontal lines represent the 
10 and 90th percentile of the test–retest data sample. Average test–
retest time span 130 ± 71 days. Each patient is identified by the same 
symbol as in Fig. 1
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increase of oxygen tension may prevent photorecep-
tors apoptosis in specific models and stages of retinal 
degeneration.
A limitation of the present study is the limited number 
of patients, which however is not uncommon in this type 
of studies, where ethical reasons tend to oppose the use 
of large samples of patients to test safety. Furthermore, 
the absence of a placebo-treated control group and the 
short duration of follow-up may reduce the reliability of 
these fascinating results.
Conclusions
In conclusion, this study showed that NGF eye drops 
administration is well tolerated without significant 
adverse effects. In a minority of patients, the treatment 
was associated with a subjective improvement of visual 
function confirmed by Goldmann visual field and fERG 
supporting the feasibility of a randomized clinical trial, 
with an estimate of the potential effect size, testing the 
neuroprotective efficacy of NGF eye-drop treatment in 
RP patients.
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